這是一項先導研究，旨在評估以 Doxorubicin + Cisplastin 進行 PIPAC 對胃癌腹膜轉移（PM）患者的成效。所有在香港威爾斯親王醫院（PWH）確診胃癌並伴有腹膜轉移的患者均會接受資格篩查。 本研究有兩個目標： 1.
適應症：Gastric Cancer Peritoneal Metastases
收案條件
納入條件
- Patients age \>= 18, \<= 80 years old
- Performance status (WHO) \<=2
- Histologically evidenced synchronous PM of gastric adenocarcinoma cancer
- Peritoneal Cancer Index (PCI) score \> 8, or \<=8 and patient not fit for cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)
- Patients with isolated ovarian metastasis could be included
- White blood cells \>3.5000/mm3; neutrophils \> 1.500/mm3; platelets \>100,000/mm3
- Creatinine \<1.5mg/dL and creatinine clearance \>60ml/min and serum total bilirubin \<2mg/dL
- Ability to give written consent prior to commencement of treatment
排除條件
- Extraperitoneal metastases including liver metastases and malignant pleural effusion. The presence of suspicious retroperitoneal lymph nodes is not an exclusion criterium.
- Patients with adenocarcinoma of Siewart I
- Bowel obstruction, not tolerating oral diet
- HER2+++ tumor with indicated for Trastuzumab therapy
- Any laparotomy during 3 months before inclusion. (Laparoscopy is not an exclusion criterium)
- Contraindicated to any drug contained in the chemotherapy regimen
- Concomitant intraperitoneal chemotherapy, immunotherapy or target therapy
- Active infectious (bacterial, viral) disease. Elevated CRP with no identified focus is not an exclusion criterium
- Pregnancy or breastfeeding
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。